First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 3.16 USD 0.64% Market Closed
Updated: Jun 13, 2024
Have any thoughts about
ADC Therapeutics SA?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
ADC Therapeutics SA

Revenue
121.4m USD
Cost of Revenue
-6m USD
Gross Profit
115.4m USD
Operating Expenses
-391.9m USD
Operating Income
-276.5m USD
Other Expenses
-105.1m USD
Net Income
-381.6m USD

Margins Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
304.1m USD
95%
-228%
-314%
US
Abbvie Inc
NYSE:ABBV
293.3B USD
66%
29%
11%
US
Amgen Inc
NASDAQ:AMGN
161.5B USD
66%
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.9B USD
87%
41%
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
113.2B USD
86%
30%
29%
AU
CSL Ltd
ASX:CSL
136.3B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
80.2B USD
76%
32%
2%
US
Moderna Inc
NASDAQ:MRNA
56.6B USD
22%
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
33.6B USD
75%
22%
12%
KR
Celltrion Inc
KRX:068270
38.9T KRW
47%
21%
17%
Country CH
Market Cap 304.1m USD
Gross Margin
95%
Operating Margin
-228%
Net Margin
-314%
Country US
Market Cap 293.3B USD
Gross Margin
66%
Operating Margin
29%
Net Margin
11%
Country US
Market Cap 161.5B USD
Gross Margin
66%
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 122.9B USD
Gross Margin
87%
Operating Margin
41%
Net Margin
39%
Country US
Market Cap 113.2B USD
Gross Margin
86%
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 136.3B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 80.2B USD
Gross Margin
76%
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 56.6B USD
Gross Margin
22%
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 33.6B USD
Gross Margin
75%
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 38.9T KRW
Gross Margin
47%
Operating Margin
21%
Net Margin
17%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CH
ADC Therapeutics SA
NYSE:ADCT
304.1m USD
487%
-98%
-88%
-291%
US
Abbvie Inc
NYSE:ABBV
293.3B USD
56%
4%
15%
13%
US
Amgen Inc
NASDAQ:AMGN
161.5B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.9B USD
24%
19%
23%
33%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
113.2B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
136.3B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
80.2B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
56.6B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
33.6B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
38.9T KRW
4%
3%
4%
3%
Country CH
Market Cap 304.1m USD
ROE
487%
ROA
-98%
ROCE
-88%
ROIC
-291%
Country US
Market Cap 293.3B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
13%
Country US
Market Cap 161.5B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 122.9B USD
ROE
24%
ROA
19%
ROCE
23%
ROIC
33%
Country US
Market Cap 113.2B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 136.3B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 80.2B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 56.6B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 33.6B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 38.9T KRW
ROE
4%
ROA
3%
ROCE
4%
ROIC
3%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More